Cytokine profile and antioxidants status in the moderate and severe COVID-19 patients : a trial of ozone therapy impact as a medicinal supplement
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
BACKGROUND: Complementary ozone therapy has been identified as a revolutionary medical technique for a number of goals and ailments. At the present, it has been shown that ozone has medicinal qualities, such as antibacterial, antifungal, and antiparasitic properties. Coronavirus (SARS-CoV-2) is quickly spread over the globe. Cytokine storms and oxidative stress seem to play a substantial role in the most of acute attacks of the disease. The aim of this research was to assess the therapeutic advantages of complementary ozone therapy on the cytokine profile and antioxidant status in COVID-19 patients.
METHODS: The statistical sample of this study included two hundred patients with COVID-19. One hundred COVID-19 patients (treatment group) received 240 ml of the patient's blood and an equal volume of O2/O3 gas at a concentration of 35-50 μg/ml daily, which gradually increased in concentration, and were kept for 5-10 days and one hundred patients (control group) received standard treatment. The secretion levels of IL-6, TNF-α, IL-1β, IL-10 cytokines, SOD, CAT and GPx were compared between control patients (standard treatment) and standard treatment plus intervention (ozone) before and after treatment.
RESULTS: The findings indicated a significant decrease in the level of IL-6, TNF-α, IL-1β in group receiving complementary ozone therapy in compared with control group. Furthermore, a significant increase was found in the level of IL-10 cytokine. Moreover, SOD, CAT and GPx levels revealed a significant increase in complementary ozone therapy group compared to control group.
CONCLUSIONS: Our results revealed that complementary ozone therapy can be used as a medicinal complementary therapy to reduce and control inflammatory cytokines and oxidative stress status in patients with COVID-19 as revealed its antioxidant and anti-inflammatory effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 31(2023), 6 vom: 12. Dez., Seite 3029-3036 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghaleh, Hadi Esmaeili Gouvarchin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10787-023-01288-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359373739 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359373739 | ||
| 003 | DE-627 | ||
| 005 | 20231226080731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-023-01288-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359373739 | ||
| 035 | |a (NLM)37436523 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghaleh, Hadi Esmaeili Gouvarchin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytokine profile and antioxidants status in the moderate and severe COVID-19 patients |b a trial of ozone therapy impact as a medicinal supplement |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a BACKGROUND: Complementary ozone therapy has been identified as a revolutionary medical technique for a number of goals and ailments. At the present, it has been shown that ozone has medicinal qualities, such as antibacterial, antifungal, and antiparasitic properties. Coronavirus (SARS-CoV-2) is quickly spread over the globe. Cytokine storms and oxidative stress seem to play a substantial role in the most of acute attacks of the disease. The aim of this research was to assess the therapeutic advantages of complementary ozone therapy on the cytokine profile and antioxidant status in COVID-19 patients | ||
| 520 | |a METHODS: The statistical sample of this study included two hundred patients with COVID-19. One hundred COVID-19 patients (treatment group) received 240 ml of the patient's blood and an equal volume of O2/O3 gas at a concentration of 35-50 μg/ml daily, which gradually increased in concentration, and were kept for 5-10 days and one hundred patients (control group) received standard treatment. The secretion levels of IL-6, TNF-α, IL-1β, IL-10 cytokines, SOD, CAT and GPx were compared between control patients (standard treatment) and standard treatment plus intervention (ozone) before and after treatment | ||
| 520 | |a RESULTS: The findings indicated a significant decrease in the level of IL-6, TNF-α, IL-1β in group receiving complementary ozone therapy in compared with control group. Furthermore, a significant increase was found in the level of IL-10 cytokine. Moreover, SOD, CAT and GPx levels revealed a significant increase in complementary ozone therapy group compared to control group | ||
| 520 | |a CONCLUSIONS: Our results revealed that complementary ozone therapy can be used as a medicinal complementary therapy to reduce and control inflammatory cytokines and oxidative stress status in patients with COVID-19 as revealed its antioxidant and anti-inflammatory effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antioxidant agents | |
| 650 | 4 | |a COVID-19 patients | |
| 650 | 4 | |a Cytokine | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a Ozone therapy | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Interleukin-10 |2 NLM | |
| 650 | 7 | |a 130068-27-8 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Ozone |2 NLM | |
| 650 | 7 | |a 66H7ZZK23N |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Superoxide Dismutase |2 NLM | |
| 650 | 7 | |a EC 1.15.1.1 |2 NLM | |
| 700 | 1 | |a Izadi, Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Javanbakht, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Ghanei, Mostafa |e verfasserin |4 aut | |
| 700 | 1 | |a Einollahi, Behzad |e verfasserin |4 aut | |
| 700 | 1 | |a Jafari, Nematollah Jonaidi |e verfasserin |4 aut | |
| 700 | 1 | |a Alishiri, Gholamhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Aslani, Jafar |e verfasserin |4 aut | |
| 700 | 1 | |a Abolghasemi, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Simonetti, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Khafaei, Mostafa |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Shi |e verfasserin |4 aut | |
| 700 | 1 | |a Saadat, Seyed Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Parvin, Shahram |e verfasserin |4 aut | |
| 700 | 1 | |a Vazifedoust, Soheil |e verfasserin |4 aut | |
| 700 | 1 | |a Alvanagh, Akbar Ghorbani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d 1996 |g 31(2023), 6 vom: 12. Dez., Seite 3029-3036 |w (DE-627)NLM090686616 |x 1568-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:6 |g day:12 |g month:12 |g pages:3029-3036 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10787-023-01288-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 6 |b 12 |c 12 |h 3029-3036 | ||